Woven EndoBridge (WEB) Aneurysm Embolization System
Microvention, Inc. · Decision date May 1, 2026
What did the FDA decide?
FDA records P170032/S021 as a supplement to PMA P170032, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 1, 2026.
FDA approval order statement
approval for an alternate manufacturer of the WEB delivery system subassembly at MicroVention Inc.s Costa Rica facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- May 1, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P170032/S021
- Regulatory pathway
- PMA supplement
- Applicant
- Microvention, Inc.
- Product code
- OPR
- Decision code
- OK30
- Decision date
- May 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intrasaccular Flow Disruption Device.
- Applicant
- Microvention, Inc.
- Product code
- OPR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170032 · Original PMA
Woven EndoBridge (WEB) Aneurysm Embolization System
P170032/S019 · Related supplement
Woven EndoBridge Aneurysm Embolization (WEB) System
P170032/S021 received
Application receipt date recorded by FDA.
P170032/S021 · FDA decision
30-Day Notice
P170032/S022 · Related supplement
Woven EndoBridge (WEB) Aneurysm Embolization System
P170032/S024 · Related supplement
Woven EndoBridge (WEB) Aneurysm Embolization System
Timeline entries are records held by MedtechLedger for P170032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Microvention, Inc. | PMA approval | Dec 31, 2018 | FDA | |
| Microvention, Inc. | PMA supplement | Mar 20, 2026 | FDA | |
| Microvention, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Microvention, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Microvention, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 35 Enterprise, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P170032/S021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

